The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
– J.P.Morgan resumes coverage of AstraZeneca with 'overweight'
* J.P.Morgan resumes coverage of drugmaker with 'overweight' rating and target price of 10,000p, implies ~22% upside to stock's last close
* Brokerage says AZN is its UK large-cap top-pick stock
* Says co's recent acquisition of rare medicines business
Alexion shows continued strong top-line growth, along with significant operating margin expansion and increased free-cash-flow generation
* Brokerage sees a number of upcoming pipeline catalysts, with the potential to drive long-term upgrades and multiple expansion
* "We believe investor concerns around 2022 earnings power are misplaced, we see the company delivering on consensus margin expansion and EPS growth expectations" - JPM
* British scientists said on Wednesday, that no new cases of a rare and severe blood clots following vaccination with AZN
COVID shot have been reported in Britain in recent weeks after a decision to restrict its use in under-40s...
* Avg. rating on AZN is "buy", median PT of 31 analysts covering AZN is 9,500p - Refinitiv data
EU looks into Pfizer, Moderna vaccine side effects
https://au.finance.yahoo.com/video/eu-looks-pfizer-moderna-vaccine-071054530.
Price performance between AstraZeneca , Pfizer and Moderna within last year
AstraZeneca down -5.6 % unfortunately
Pfizer. Up. +25.5 %
Moderna. Up. + 395 %
In my opinion AstraZeneca is undervalue value compare to other two and safer bet .
Give me single reason why should blue chip company like AstraZeneca trade at this low level ? Despite It had good news last fews days ,it will pay fat dividend next fews days , health shares around the world like Pfizer and Moderna , trade at all time home .
Is manipulation in uk Stockmarket or no regulations or what is going on with index funds they control the market up and down .
AstraZeneca should delist from the UK Stockmarket or the FTSE and trade only in USA market to trade on the fair value because the UK investors and institutions didn’t recognise the value , healthcare index in USA today all time high , Pfizer and Moderna but in UK we have good quality company like AstraZeneca we devalue them . .
AstraZeneca added Thursday that group net profit jumped 40 percent to $2.1 billion in the first half.
Total revenues increased by almost a quarter to $15.5 billion.
Stripping out the COVID vaccine, total revenues increased by 14 percent to about $14.4 billion.
"AstraZeneca has delivered another period of strong growth thanks to robust performances across all regions and disease areas," said Soriot.
"As a result, we have delivered further earnings progression, supported ongoing launches, and continued our investment in research and development."
'Enormous milestone'
Longer term growth would be supported by the $39-billion purchase of US biotech company Alexion.
The blockbuster deal was cleared by Britain's competition watchdog earlier this month.
"Just last week, we completed the acquisition of Alexion, an enormous milestone that will enable us to enhance our pipeline in rare diseases and immunology," the CEO added.
As a result, the company lifted its full-year 2021 guidance.
Revenues excluding vaccine sales are now forecast to grow by a low-twenties percentage this year.
AstraZeneca added Thursday that group net profit jumped 40 percent to $2.1 billion in the first half.
Total revenues increased by almost a quarter to $15.5 billion.
Stripping out the COVID vaccine, total revenues increased by 14 percent to about $14.4 billion.
"AstraZeneca has delivered another period of strong growth thanks to robust performances across all regions and disease areas," said Soriot.
"As a result, we have delivered further earnings progression, supported ongoing launches, and continued our investment in research and development."
'Enormous milestone'
Longer term growth would be supported by the $39-billion purchase of US biotech company Alexion.
The blockbuster deal was cleared by Britain's competition watchdog earlier this month.
"Just last week, we completed the acquisition of Alexion, an enormous milestone that will enable us to enhance our pipeline in rare diseases and immunology," the CEO added.
As a result, the company lifted its full-year 2021 guidance.
Revenues excluding vaccine sales are now forecast to grow by a low-twenties percentage this year.
Our market is a joke and manipulation , I was expecting to see AstraZeneca share price up 100 points , look how they manipulate the price down till they close the short or they buy new long at cheap price then move the price up .
Worst 2 Stockmarket in the world , FTSE 100 and Hang seng index in Hong Kong ,
The worst performance , manipulation .
I’m waiting for day to close my positions in UK and I will never invest in UK Stockmarket again
Unqualified and dishonest: the ‘experts’ who undermined confidence in AstraZeneca will cost Australians’ lives
https://www.smh.com.au/national/unqualified-and-dishonest-the-experts-who-undermined-confidence-in-astrazeneca-will-cost-australians-lives-20210722-p58c1f.html